Engineering adolescence: maturation of human pluripotent stem cell-derived cardiomyocytes.
The discovery of human pluripotent stem cells (hPSCs), including both human embryonic stem cells and human-induced pluripotent stem cells, has opened up novel paths for a wide range of scientific studies. The capability to direct the differentiation of hPSCs into functional cardiomyocytes has provided a platform for regenerative medicine, development, tissue engineering, disease modeling, and drug toxicity testing. Despite exciting progress, achieving the optimal benefits has been hampered by the immature nature of these cardiomyocytes. Cardiac maturation has long been studied in vivo using animal models; however, finding ways to mature hPSC cardiomyocytes is only in its initial stages. In this review, we discuss progress in promoting the maturation of the hPSC cardiomyocytes, in the context of our current knowledge of developmental cardiac maturation and in relation to in vitro model systems such as rodent ventricular myocytes. Promising approaches that have begun to be examined in hPSC cardiomyocytes include long-term culturing, 3-dimensional tissue engineering, mechanical loading, electric stimulation, modulation of substrate stiffness, and treatment with neurohormonal factors. Future studies will benefit from the combinatorial use of different approaches that more closely mimic nature's diverse cues, which may result in broader changes in structure, function, and therapeutic applicability.
Xiulan
X
Yang
Lil
L
Pabon
Charles E
CE
Murry
D000818:Animals; D002454:Cell Differentiation / Q000502:physiology*; D060846:Cell Engineering / Q000379:methods*; D002478:Cells, Cultured; D005818:Genetic Engineering; D006801:Humans; D057026:Induced Pluripotent Stem Cells / Q000502:physiology* / Q000637:transplantation; D023421:Models, Animal; D032383:Myocytes, Cardiac / Q000502:physiology* / Q000637:transplantation; D039904:Pluripotent Stem Cells / Q000502:physiology / Q000637:transplantation; D013997:Time Factors
disease modeling; human pluripotent stem cell–derived cardiomyocytes; maturation; pharmacologic screening